Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:02 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

NCT04531176 · The Cleveland Clinic · PHASE4 · terminated · last registry update 2024-09-19 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Kind	Quote	Our category	Source
Stated	“After an unplanned yet IRB approved interim analysis, it was found that there was not a significant difference between the 3 arms of the study. The study was closed due to futility. All Patients are off study and this study will not resume.”	–	Registry record, The Cleveland Clinic

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against GLP1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

Internal portfolio and board discussions
Unpublished trial data and interim analyses
Terms of any partner or licence decision